About the ARCHITECT family of instrumentsThe ARCHITECT family of analyzers and includes the i1000SR i2000SR for immunoassays, the c4000, c8000 and c16000 for clinical chemistry and ci4100, ci8200 and ci16200 integrated immunoassay / chemistry systems. Abbott’s unique technologies include the Robotic Sample Handler to prioritize emergency measures tests, sample clot and bubble detection to verify sampling integrity, and flex rate CHEMIFLEX and assay technologies cliquez pour en savoir plus more info . ARCHITECT systems use identical easy-to use software and common reagents for all family members.
About Abbott DiagnosticsAbbott Diagnostics is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, Reference labs, blood banks, physician offices and clinics. With more than 69,000 institutional customers in more than 100 countries, Abbott’s diagnostic products offer customers automation, convenience, cost effectiveness and flexibility. Abbott has helped. The practice of medical diagnosis from an art to a science through the company’s commitment to improving patient care and lowering overall costs The history of Abbott Diagnostics is filled with examples recognize first-of – a-kind products and significant technological advances, including the development of the first diagnostic test for HIV filled.
Increase warnings on tobacco packages: longer more graphics, tobacco users is more paying attention them. The World Trade Organization the availability of tobacco healthcare / economic Details to the general public: lot of of tobacco users, politicians and even by health professionals are largely unknown and simply vaguely aware of of the , other cancers, heart disease, lung disease, pre-and post-natal conditions of caused by tobacco use.
Ask a new American Cancer Society paper describes 21 challenges and the needs of global tobacco check, to be addressed to wide range of issues and expertise necessary the rising flood the rising tide tobacco consumption the world , especially in the low and middle income nations that are the target multinational tobacco industry. The report shall be Already a published Added and displayed in the January / February edition of CA: A Cancer Journal on Clinical.